to-severe hypertension. Hyperthyroidism. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Warnings/Precautions:
High abuse potential. Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder. Depression. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. eva luate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reeva luate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
See Contraindications. Avoid concomitant antacids. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide, some thiazides), propoxyphene. Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May antagonize effects of adrenergic blockers, antihistamines, veratrum alkaloids, antihypertensives. May potentiate effects of tricyclic antidepressants, meperidine, norepinephrine. May delay absorption of phenytoin, phenobarbital, ethosuximide. Monitor effects when concomitant PPIs. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid tests.
Pharmacological Class:
CNS stimulant.
Adverse Reactions:
Palpitations, tachycardia, BP increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido change, prolonged erection, rhabdomyolysis; serious cardiovascular events, visual disturbances.
Generic Availability:
NO
How Supplied:
Tabs—100
Indications for EVEKEO:
Narcolepsy.
Adults and Children:
Give first dose upon awakening and additional doses at 4–6hr intervals. Usual range 5–60mg/day. <6yrs: not recommended. 6–12yrs: initially 5mg daily, may increase by 5mg/day at weekly intervals. ≥12yrs: initially 10mg daily; may increase by 10mg/day at weekly intervals.
Contraindications:
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate-to-severe hypertension. Hyperthyroidism. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Warnings/Precautions:
High abuse potential. Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder. Depression. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. eva luate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reeva luate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
Int
